CoChat

Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes

Robinson, Delbert G., Woerner, Margaret G., Napolitano, Barbara, Patel, Raman C., Sevy, Serge M., Gunduz-Bruce, Handan, Soto-Perello, Jose M., Mendelowitz, Alan, Khadivi, Ali, Miller, Rachel, McCormack, Joanne, Lorell, Beth S., Lesser, Martin L., Schooler, Nina R., Kane, John M. · 2006 · American Journal of Psychiatry
Cited by 107

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders. METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day). RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%). Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria. Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine. Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone. Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone. CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable. Olanzapine may have an advantage for motor side effects. Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/ajp.2006.163.12.2096

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 24

  1. 10.1038/sj.npp.1300157 · DOI · Paper page
  2. 10.1093/oxfordjournals.schbul.a033413 · DOI · Paper page
  3. 10.1176/appi.ajp.162.5.947 · DOI · Paper page
  4. 10.1176/appi.ajp.160.8.1396 · DOI · Paper page
  5. 10.4088/JCP.v64n0913 · DOI · Paper page
  6. 10.1093/oxfordjournals.schbul.a033476 · DOI
  7. 10.1093/schbul/sbi032 · DOI
  8. Lieberman JA, 2005, N Engl J Med, 354, 300
  9. 10.1016/S0920-9964(98)00105-4 · DOI · Paper page
  10. 10.1097/01.jcp.0000130558.86125.5b · DOI · Paper page
  11. 10.1097/00004714-199710000-00010 · DOI · Paper page
  12. 10.1176/appi.ajp.158.5.765 · DOI · Paper page
  13. 10.1097/00019442-200311000-00008 · DOI
  14. 10.1056/NEJMe058200 · DOI
  15. 10.1176/appi.ps.52.7.967 · DOI · Paper page
  16. 10.4088/JCP.v62n0208 · DOI
  17. 10.1089/104454602760386941 · DOI
  18. 10.1176/appi.ajp.159.4.655 · DOI · Paper page
  19. 10.1056/NEJMra012586 · DOI · Paper page
  20. 10.1176/appi.ps.54.8.1155 · DOI · Paper page
  21. 10.3109/10401230309085669 · doi:10.3109/10401230309085669
  22. 10.1001/archinte.160.7.898 · DOI · Paper page
  23. American Diabetes Association, 2001, Diabetes Care, 24, S5, 10.2337/diacare.24.1.5 · DOI · Paper page
  24. 10.1056/NEJMoa021423 · DOI · Paper page

Cited by

See all 107

Metadata

Authors
Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Sevy, S. M., Gunduz-Bruce, H., Soto-Perello, J. M., Mendelowitz, A., Khadivi, A., Miller, R., McCormack, J., Lorell, B. S., Lesser, M. L., Schooler, N. R., & Kane, J. M.
Venue
American Journal of Psychiatry
Published
2006-12
Volume
163
Issue
12
Pages
2096-2102
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2107920654
Cited by
107
References
4
FWCI
7.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes. https://app.cochat.ai/papers/10.1176/ajp.2006.163.12.2096
The paper
Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Sevy, S. M., Gunduz-Bruce, H., Soto-Perello, J. M., Mendelowitz, A., Khadivi, A., Miller, R., McCormack, J., Lorell, B. S., Lesser, M. L., Schooler, N. R., & Kane, J. M. (2006). Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes. American Journal of Psychiatry. https://doi.org/10.1176/ajp.2006.163.12.2096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.